SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 – 15, 2021, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20 – 23, 2021, and the 2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021.
Details on the presentations can be found below.
H.C. Wainwright 23rd Annual Global Investment Conference
Corporate presentation will be available on-demand to conference
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 21, 2021
4:35 PM ET
2021 Cantor Virtual Global Healthcare Conference
September 30, 2021
8:40 AM ET
A replay of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit presentation will be available on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma. Viracta is also pursuing application of its inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Chief Operating Officer and Chief Financial Officer